Research progress in positron imaging agents for Alzheimer disease

Alzheimer disease (AD) is one of the most common neurodegenerative diseases in the elderly. The symptoms of AD begin with mild memory difficulties and gradually evolve into cognitive dysfunction, complex daily activity disorders and so on. At present, the early and differential diagnosis of AD are still challenging, and biomarkers such as beta amyloid protein (Aβ) and Tau protein play a more and more important role in the diagnosis of AD. This paper reviews the positron imaging agents related to the diagnosis of AD, in order to let more medical workers understand the new nuclear medical imaging technology, so as to make early diagnosis and treatment of AD and delay the deterioration of the disease.